glp 1 glucagon dual receptor agonist Schematic illustration of monoagonists, agonists and triple Frontiers | GLP−1 receptor agonists

M2 macrophages in kidney disease: biology, therapies, and perspectives

Still, insurance coverage and cost considerations mean both drugs remain relevant, and patient-centred conversations about therapy choice are critical. GLP-1s beyond weight loss as multi-system therapies Liver disease and metabolic steatohepatitis Non-alcoholic fatty liver disease (NAFLD) and the more severe metabolic dysfunction-associated steatohepatitis (MASH) have few effective pharmacologic treatments

When engaged, the receptor initiates cascades that influence metabolism, inflammation, cell survival, and neural activity

Direct head-to-head comparisons have not been done

Simon R, Lahiri SW